Article
Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years.
Antimicrobial agents and chemotherapy - 1 Apr 1997
Winters M A, Shafer R W, Jellinger R A, Mamtora G, Gingeras T, Merigan T C
Abstract excerpt
The genetic mechanisms of human immunodeficiency virus type 1 (HIV-1) resistance to dideoxyinosine (ddI) in vivo have been described based on data from primary HIV-1 isolates. To better define the spectrum of HIV-1 reverse transcriptase (RT) changes occurring during ddI therapy, we determined the...
Topics
- Anti-HIV Agents
- Didanosine
- Double-Blind Method
- Drug Resistance, Microbial
- Genotype
- HIV Infections
- HIV Reverse Transcriptase
- Humans
- Mutation
- Polymerase Chain Reaction
- RNA, Viral
- Recombinant Proteins
- Reverse Transcriptase Inhibitors
- Zidovudine